QIAGEN NV (QIA BE) stock market data APIs
€40.656
0(0%)
as of March 5, 2026
Try our APIs with
free plan!
QIAGEN NV Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for QIA.BE.
Prev. Close
40.656
Open
40.656
High
40.656
Low
40.656
52 wk Range
33.1998-44.0974
Market Cap
10 941 M
EPS
0.55
Dividends (Yield)
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get QIAGEN NV data using free add-ons & libraries
Get QIAGEN NV Fundamental Data
QIAGEN NV Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: 0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
QIAGEN NV News
New
Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030
Company Logo The market for immunoassays targeting neurological biomarkers is driven by the global rise in neurological disorders, increasing demand for early diagnostics, AI integration enhancing bi...
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line SEATTLE, Wash. & VENLO...
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 VENLO, Netherlands,...
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82%
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading actions A total of 13 investors have a majority stake in the company with 51% owners...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
